Cyrus Biotechnology Exhibits at the PEGS Protein Engineering Summit in Boston, April 30th – May 3rd

SEATTLE, April 18, 2018 — Cyrus Biotechnology, Inc., a biotechnology software company offering the most advanced protein modeling and design capabilities to the Biopharmaceutical, Synthetic Biology, Chemical, and Consumer Products industries is pleased to announce its participation in the 14th Annual PEGS Boston Protein Engineering Summit in Boston, from April 30th through May 3rd.

Dr. David Pearlman, Senior Fellow and Director of Customer Experience at Cyrus Bio, and Rosario Caltabiano, Executive VP of Sales, will attend the conference and discuss the latest advances in in silico protein engineering at booth 539 in the Boston Seaport World Trade Center Exhibit Hall. 

The Rosetta software package, from the RosettaCommons, is the premier software platform for advanced computational protein engineering. Cyrus has implemented the Rosetta stack with an easy to use interface on a public computing cloud, resulting in high reliability software with high performance and usability in a secure multi-tenant model. R&D organizations can remove large capital expenditures, avoid over- or under-provisioning, and maximize scientific output.

In silico modeling and design of proteins is becoming increasingly relevant to the pharmaceutical industry, as investment in research, development and clinical trials of biologic therapeutics continues to grow. Cyrus Bench® software, and the underlying Rosetta software package, are already leveraged by many global pharmaceutical organizations and are at the nexus of this major trend. Cyrus customers can apply the most advanced and validated in silico protein engineering science through an intuitive user interface for:

  • Protein Structure Prediction (best overall performance at CASP and CAMEO)
  • Protein Stabilization
  • Computational Affinity Maturation (Interface Design)
  • Prediction of Immunogenic Epitopes
  • Removal of Identified Liabilities
  • Protein Structure Optimization and Design
  • Antibody Engineering
  • Antigen Design

 

Background

Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo. Cyrus is funded by experienced investors in Tech and Biotech including Trinity Ventures, Orbimed Advisors, SpringRock Ventures, W Fund and others.

NOTICE: The information contained in this document is dated as of April 18, 2018.  Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date.  This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties.  Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Cyrus Press Release 04/18/2018

 

Contact Lucas Nivon
lucas@cyrusbio.com
206-258-6561

New Design Tool: FLEX DESIGN

Our newest CAD design tool is called Flex Design. This is similar to our current Design tool, but allows more backbone changes to occur in the area of design. This will allow more mutations to be sampled because the backbone can adjust to changes that are larger, smaller, or have a different polar nature. The backbone will only be allowed to make minor adjustments (within 0.5 Å ) in the region of design and the region up to 8 Å away.

Cyrus’s FlexDesign Action runs Rosetta’s CoupledMoves protocol, which has emerged as the best generalized tool for predicting affinity-improving mutations at either a protein/protein or a protein/small-molecule interface, when starting from an existing interface in need of improvement.

For a full description of Flex Design and how it relates to our original Design tool and a tool called Relax Design that will be released soon click here.

For a tutorial on how to run Flex Design click here.

Quick Mutating CAD Cyrus Biotechnology

Quick Mutating